A-485,≥98% (HPLC)

别名:N-(4-氟苄基)-2-((R)-5-(3-甲基脲基)-2',4'-二氧代-2,3-二氢螺[茚-1,5'-恶唑烷]-3'-基)-N-((S)-1,1,1-三氟丙-2-基)乙酰胺;N-(4-fluorobenzyl)-2-((R)-5-(3-methylureido)-2′,4′-dioxo-2,3-dihydrospiro[indene-1,5′-ozazolidine]-3′-7 yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, Spiro[1H-indene-1,5′-oxazolidine]-3′-acetamide, N-[(4-fluorophenyl)methyl]-2,3-dihydro-5-[[(methylamino)carbonyl]amino]-2′,4′-dioxo-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, (1R)-

Empirical Formula (Hill Notation): C25H24F4N4O5 CAS号: 1889279-16-6 分子量: 536.48 MDL编号: MFCD31619258
制造商品牌: 西格玛 Sigma-Aldrich
货号(SKU): SML2192
CAS号: 1889279-16-6
MDL号: MFCD31619258
签订合同 √ 正规发票 √ 技术支持 √ 质量保障 √ 全程可追溯 √
¥2,049.13

说明

应用

A-485 has been used as a p300 regulated RelA acetylation inhibitor to study the effect of fatty acid oxidation (FAO) derived cytoplasmic acetyl-CoA on CD47 transcription and protein stability via citrate/acetyl-CoA mediated RelA acetylation in glioblastoma.[1]
 

生化/生理作用

A-485 exhibits an anti-tumor effect and may show therapeutic effects against the growth hormone pituitary adenoma (GHPA). It can specifically block the acetylation of histone H3 lysine 27 (H3K27) and lysine 18 (H3K18) sites catalyzed by p300.[2]
A-485 is a potent and selective catalytic inhibitor of the p300 and CREB-binding protein (CBP) histone acetyltransferases (HATs) with an IC50 value of 60 nM. A-485 was most active against haematological malignancies including most multiple myeloma cell lines as well as androgen receptor-positive prostate cancer. It was also shown to inhibit the proliferation of castration-resistant prostate cancer cells and in vivo tumour growth in SCID mice.
 
 

属性

质量水平

100

测定

≥98% (HPLC)

形式

powder

旋光性

[α]/D +40 to +50°, c = 0.5 in methanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES string

CNC(NC1=CC=C2C(CC[C@]23C(N(CC(N(CC4=CC=C(F)C=C4)[C@@H](C)C(F)(F)F)=O)C(O3)=O)=O)=C1)=O

 

安全信息

储存分类代码

11 - Combustible Solids

WGK

WGK 3

商品规格
属性名称属性值
储存温度 Storage temp.2-8°C冷藏
全球实时库存 Availability √美国St. Louis ≥ 20 | 欧洲Eur. ≥ 16 | 東京Tokyo ≥ 5 | 香港与北京 ≥ 20